Effectors of Hyperlipidemia among HIV/AIDS patients with second-line antiretroviral therapy based on register data

Chunling Yang; Dongli Wang; Yanmin Ma; Zhibin Liu; Huijun Guo; Feng Sang; Qianlei Xu; Yantao Jin

doi:10.2174/1570162X20666220805103411

Effectors of Hyperlipidemia among HIV/AIDS patients with second-line antiretroviral therapy based on register data

Curr HIV Res. 2022 Aug 5;20(5):373-379. doi: 10.2174/1570162X20666220805103411. Online ahead of print.

Authors

Chunling Yang¹, Dongli Wang¹, Yanmin Ma², Zhibin Liu^{1

3}, Huijun Guo³, Feng Sang⁴, Qianlei Xu^{1

3}, Yantao Jin³

Affiliations

¹ The First Clinical Medical School, Henan University of Chinese Medicine, Zhengzhou, China.
² Center for AIDS/STD Control and Prevention, Center for Disease Control and Prevention of Henan Province, Zhengzhou, China.
³ Department of Acquired Immune Deficiency Syndrome Treatment and Research Center, The First Affiliated Hospital of Henan University of Chinese Medicine, Zhengzhou, China.
⁴ Henan Key Laboratory of Viral Diseases Prevention and Treatment of Traditional Chinese Medicine, Henan University of Chinese Medicine, Zhengzhou, China.

Abstract

Objective: In this study, we aimed to determine the prevalence and effectors of hyperlipidemia among people living with HIV/AIDS (PLWHA) and taking second-line antiretroviral therapy (ART) using registry data in central China.

Methods: We conducted a cross-sectional study and collected information of PLWHA on second-line ART during 2018 from two medical registries. Hyperlipidemia was defined according to the 2016 Chinese guidelines for the management of dyslipidemia in adults. Univariate and multivariate logistic regression analyses were performed to explore the influencing factors of hyperlipidemia. We calculated odds ratios (ORs) and 95% confidence intervals (CIs).

Results: A total of 2886 PLWHA taking second-line ART were included in this study, and 978 (33.9%) had hyperlipidemia. Female patients, those with hyperglycemia, and patients with CD4+ cell counts >500 cells/μL had a higher prevalence of hyperlipidemia with 37.0%, 49.0%, and 41.3%, respectively. Multivariate analysis showed that CD4+ cell count 350-500 cells/μL (OR=1.72, 95% CI: 1.26-2.38), CD4+ cell count >500 cells/μL (OR=2.49, 95% CI: 1.85-3.38), and FPG >6.2 mmol/L (OR=2.08, 95% CI:1.64-2.65) were risk factors for hyperlipidemia. Male sex (OR=0.72, 95% CI: 0.61-0.85) and Hb <110 g/L (OR=0.59, 95% CI: 0.45-0.76) were protective factors against hyperlipidemia.

Conclusions: PLWHA on second-line ART had a higher prevalence of hyperlipidemia. Gender, CD4+ cell count, FPG, and hemoglobin were influencing factors of hyperlipidemia.

Keywords: AIDS; HIV; cross-sectional study; hyperlipidemia; second-line ART.

Abstract

Grants and funding